News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtablesShorts
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors
Clinical Forum Insights

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Clinical Forum Insights
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Vaccines in America|
Antibiotics Deconstructed|
Bench to Bedside With SIDP|
Antimicrobial Stewardship|
Hepatitis
Advertisement

News

Advertisement

Nine New Yorkers Test Positive for Zika Virus

ByCaitlyn Fitzpatrick
Published: February 6th 2016 | Updated: October 5th 2020

The Zika virus has made its way to the East Coast as nine patients have the mosquito-borne illness.

  • Prev
  • 1
  • More pages
  • 353
  • 354
  • 355
  • 356
  • 357
  • 358
  • 359
  • 360
  • 361
  • 362
  • Prev
Advertisement
Advertisement

Trending on Contagion Live

1

Doravirine/Islatravir Combination Maintains Virologic Suppression Through 96 Weeks

2

Switch to Dovato Linked to Lower Rates of Steatotic Liver Disease Vs Biktarvy at 96 Weeks

3

Novel Single-Tablet Regimen Demonstrates Noninferiority to Standard HIV Therapy

4

Switching to Doravirine/Islatravir Maintains Viral Suppression Through 96 Weeks

5

Antiviral Emerges as a Highly Potent, First-in-Class Candidate for Hepatitis E

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us